STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
Eli Lilly has achieved a significant milestone by ranking first in both innovation and invention categories in a recent pharmaceutical R&D performance index. This ranking, produced by IDEA Pharma, highlights the company's success in generating revenue from new products and its extensive drug development efforts. This is the first instance of a single company topping both categories in the index's history.
- ▪Eli Lilly ranked No. 1 in both innovation and invention categories according to IDEA Pharma.
- ▪The innovation category considers revenue from new products and drug approvals, while invention looks at drugs in development and R&D investment.
- ▪This is the first time a single company has achieved the top ranking in both categories.
STAT News files mainly under health. We currently carry 225 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT |
| Canonical URL | https://www.statnews.com/2026/05/19/pharma-rankings-innovation-invention/?utm_campaign=rss |
| Publication time | Tue, 19 May 2026 12:00:00 +0000 |
| Retrieval time | 2026-05-19T12:04:57.562Z |
| Last seen | 2026-05-19T12:19:54.874Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | zUsJtPU6Za8h · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
STAT PlusPharma Eli Lilly tops prominent rankings on pharma R&D performance Report by UKlooks at progress on ‘innovation’ and ‘invention’ Manage alerts for this article Email this article Share this article Eli Lilly and Company rings the opening bell of the New York Stock Exchange this month. The drug company’s labs were rated No. 1 in two key categories.ANGELA WEISS / AFP via Getty Images By Allison DeAngelis and Matthew HerperMay 19, 2026 Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
